The company has yet to file a prospectus for the IPO. If the IPO goes according to plan, it could result in a valuation of $600 million for EndoChoice, according to the report.
More articles on gastroenterology:
To survive in GI, be prepared
Do gastroenterologists underestimate IBD severity?
15 gastroenterologists making headlines this month
